<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210815052186N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-05</date_registration>
      <primary_sponsor>Khoram-Abad University of Medical Sciences</primary_sponsor>
      <public_title>"The Effect of Garlic Extract on Lowering Blood Pressure in Prehypertensive Individuals"</public_title>
      <acronym></acronym>
      <scientific_title>The Effects of Garlic Extract(Dosage Form) on Blood Pressure in Pre-Hypertensive Individuals and Measuring Lipid Profiles and Nitric Oxide Metabolites in the Individuals</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>110</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58303</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: In order to equalize the distribution of two important confounders of age and sex, classes based on these two variables are created as "age group 30 to 50 years / age group 50 to 70 years" and "men / women" and then randomly Block Randomization is divided into two groups of treatment and control. The size of each block is 4 items, so that 6 different combinations of 4 blocks are created and are selected randomly by placing the blocks. Using this method, the sample size in the two study arms will be equal (balance) and the difference between the two groups in terms of sample size will be a maximum of half a block (two people). Using this method of random allocation, maximum power can be expected in the study results.All tests will be performed using stata14 software, Blinding description: In this study, volunteers receiving medication are blind to the study. Also, the main researcher who has other roles such as patient care, data collection and analysis, and evaluation of outcomes is blind to the study.The patient will receive the drug (intervention or control) in sealed envelopes that are coded. Coding is done by the design partner and the researcher (who also has other roles) as well as the patient in relation to the contents of the envelope, They are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Prehypertension.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The intervention group will receive a 500 mg capsule containing standardized garlic extract (allicin, The exact dose will be determined during the practical work), The study period will be eight weeks (56 days), the daily dose of the capsule for the intervention group is two per day. Intervention 2: Control group: The control or comparison group will receive a 500 mg capsule containing starch (containing 500 mg of starch).The study period will be eight weeks (56 days), the daily dose of the capsule for the control group is two per day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is "There is no more information."</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Afshin Nazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Medicine, Campus of Lorestan University of Medical Sciences, 4 km of Khorramabad-Borujerd road</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6815144316</zip>
        <telephone>+98 66 3332 3704</telephone>
        <email>nazary257@yahoo.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elham Rahmatinia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Medicine, Campus of Lorestan University of Medical Sciences, 4 km of Khorramabad-Borujerd road</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6815144316</zip>
        <telephone>+98 66 3332 3704</telephone>
        <email>Elham_rahmatinia@ymail.com</email>
        <affiliation>Khoram-Abad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>"People in Their 30s and 70s (Men and Women) Who Have Recently or At Least Three Months Received a Diagnosis of Pre-hypertension"</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>People with Allergies to Garlic and its Side Effects
People with Cardiovascular Problems and Diseases.
Patients Who Have Previously been Diagnosed with High Blood Pressure and are Taking Antihypertensive Drugs.
People with Diabetes.
People who Have recently had surgery.
People Who Have Recently Received Anesthetics.
People with Blood Disorders Who are Taking Anticoagulants
People with a History of Gallstones.
People with a History of Hypoglycemia.
Pregnant and Lactating Women</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I10</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Essential (primary) hypertension</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The intervention group will receive a 500 mg capsule containing standardized garlic extract (allicin, The exact dose will be determined during the practical work), The study period will be eight weeks (56 days), the daily dose of the capsule for the intervention group is two per day.</i_keyword>
      <i_keyword>Control group: The control or comparison group will receive a 500 mg capsule containing starch (containing 500 mg of starch).The study period will be eight weeks (56 days), the daily dose of the capsule for the control group is two per day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure (Systolic, Diastolic, Pulse pressure, Mean arterial pressure). Timepoint: "Measurement of blood pressure at the beginning of the study (before the intervention) and 4 weeks after the intervention and at the end of the study (8 weeks after the start of the study)". Method of measurement: "Mercury Barometer".</prim_outcome>
      <prim_outcome>Nitric oxide metabolite level. Timepoint: Before the intervention, four weeks after the intervention, end of the intervention (eight weeks after the intervention). Method of measurement: Grace method.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Before the intervention, four weeks after the intervention, end of the intervention (eight weeks after the intervention). Method of measurement: Autoanalyzer device.</prim_outcome>
      <prim_outcome>Cholesterol. Timepoint: Before the intervention, four weeks after the intervention, end of the intervention (eight weeks after the intervention). Method of measurement: Autoanalyzer device.</prim_outcome>
      <prim_outcome>Low Density Lipoprotein (LDL). Timepoint: Before the intervention, four weeks after the intervention, end of the intervention (eight weeks after the intervention). Method of measurement: Autoanalyzer device.</prim_outcome>
      <prim_outcome>High Density Lipoprotein (HDL). Timepoint: Before the intervention, four weeks after the intervention, end of the intervention (eight weeks after the intervention). Method of measurement: Autoanalyzer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Khoram-Abad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-07-05</approval_date>
        <contact_name>Ethics Committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>School of Medicine, Campus University of Medical Sciences, 4 km of Khorramabad-Borujerd road Khorramabad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
